20 (AIDX) Current Deferred Revenue (2024 - 2026)

20's (AIDX) quarterly Current Deferred Revenue came in at $487722.0 in Q1 2026, up 6.8% on a QoQ basis from $456687.0 in Q4 2025.

20 (AIDX) Current Deferred Revenue (2024 - 2026) Analysis & Trends

20 (AIDX) has 3 years of Current Deferred Revenue data on file, last reported at $487722.0 in Q1 2026.

Quarterly Current Deferred Revenue changed N/A year-over-year to $487722.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $487722.0 (changed N/A YoY) and the FY2025 annual result came in at $456687.0, down 12.25% from the prior year.
Current Deferred Revenue advanced to $487722.0 in Q1 2026, from $456687.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $520451.0 in Q4 2024 to a low of $456687.0 in Q4 2025.
A 3-year average of $488286.7 and a median of $487722.0 in 2026 frame the typical range for Current Deferred Revenue.
The widest YoY moves for Current Deferred Revenue: up 12.25% in 2025, down 12.25% in 2025.
Tracing AIDX's Current Deferred Revenue over 3 years: stood at $520451.0 in 2024, then dropped by 12.25% to $456687.0 in 2025, then grew by 6.8% to $487722.0 in 2026.
The last three Current Deferred Revenue figures came in at $487722.0 (Q1 2026), $456687.0 (Q4 2025), and $520451.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn
10	20	5.60 Mn	1.05 Mn	304,727.00

Download Data